4,786 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Purchased by Goldstone Financial Group LLC

Goldstone Financial Group LLC bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the biotechnology company's stock, valued at approximately $547,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio lifted its position in shares of Corcept Therapeutics by 269.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 2,086 shares in the last quarter. Van ECK Associates Corp acquired a new position in Corcept Therapeutics in the 4th quarter valued at $4,483,000. HighTower Advisors LLC lifted its holdings in Corcept Therapeutics by 30.7% in the 4th quarter. HighTower Advisors LLC now owns 93,677 shares of the biotechnology company's stock valued at $4,720,000 after purchasing an additional 22,011 shares in the last quarter. New York State Teachers Retirement System boosted its stake in Corcept Therapeutics by 3.0% during the 4th quarter. New York State Teachers Retirement System now owns 128,232 shares of the biotechnology company's stock worth $6,462,000 after purchasing an additional 3,789 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Corcept Therapeutics by 2.7% during the fourth quarter. JPMorgan Chase & Co. now owns 259,902 shares of the biotechnology company's stock worth $13,096,000 after buying an additional 6,832 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CORT. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Wall Street Zen lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Truist Financial set a $135.00 target price on Corcept Therapeutics in a report on Tuesday, May 6th. HC Wainwright cut their price target on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Piper Sandler boosted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research note on Thursday, April 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.25.

Corcept Therapeutics Trading Up 1.2%

NASDAQ:CORT traded up $0.84 on Monday, hitting $70.90. The stock had a trading volume of 806,952 shares, compared to its average volume of 1,139,382. The company has a fifty day moving average price of $71.49 and a two-hundred day moving average price of $64.48. Corcept Therapeutics Incorporated has a 1-year low of $28.04 and a 1-year high of $117.33. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 56.27 and a beta of 0.19.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, meeting analysts' consensus estimates of $0.17. The firm had revenue of $157.21 million for the quarter, compared to analysts' expectations of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm's quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.25 earnings per share. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Joseph Douglas Lyon sold 421 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $60.58, for a total value of $25,504.18. Following the sale, the insider now directly owns 9,009 shares of the company's stock, valued at approximately $545,765.22. The trade was a 4.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 1,974 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $60.83, for a total transaction of $120,078.42. Following the completion of the transaction, the chief executive officer now owns 3,017,437 shares in the company, valued at approximately $183,550,692.71. This represents a 0.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 362,325 shares of company stock valued at $30,509,238 in the last quarter. Insiders own 20.80% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.